KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Inventory (2016 - 2025)

Astrazeneca (AZN) has 3 years of Inventory data on record, last reported at $6.6 billion in Q4 2025.

  • For Q4 2025, Inventory rose 24.0% year-over-year to $6.6 billion; the TTM value through Dec 2025 reached $6.6 billion, up 24.0%, while the annual FY2025 figure was $6.6 billion, 24.0% up from the prior year.
  • Inventory reached $6.6 billion in Q4 2025 per AZN's latest filing, up from $5.3 billion in the prior quarter.
  • Across five years, Inventory topped out at $6.6 billion in Q4 2025 and bottomed at $5.3 billion in Q4 2024.
  • Average Inventory over 3 years is $5.8 billion, with a median of $5.4 billion recorded in 2023.
  • Peak YoY movement for Inventory: decreased 2.51% in 2024, then grew 24.0% in 2025.
  • A 3-year view of Inventory shows it stood at $5.4 billion in 2023, then decreased by 2.51% to $5.3 billion in 2024, then increased by 24.0% to $6.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $6.6 billion in Q4 2025, $5.3 billion in Q4 2024, and $5.4 billion in Q4 2023.